Dr. Martin has more than 20 years' global leadership experience in the Biopharmaceutical industries. He started his career at Sandoz Biopharmaceuticals as a global program head responsible for its filgrastim and rituximab biosimilars programs and later as head of global pre-clinical and clinical development. He also set up the strategy, portfolio and business development functions. In 2010, Dr. Martin moved to leading Polish generics firm Polpharma to set up its biologics business being promoted to leadership positions of increasing responsibility up to Chief Scientific Officer of Polpharma Biologics. In 2018, he moved to Canada's Apotex to become President of its global Biosimilars and complex generics Business Unit, Apobiologix. After his return to Germany in 2020, he became CEO of the immune tolerance biotech Topas Therapeutics before setting himself up as an independent consultant advising clients both in biotech and generics as well as in Private Equity and Venture Capital. Prior to joining EirGenix, Dr. Martin was also CEO of US immunology start-up Nodal Therapeutics.

Dr. Martin holds a PhD in molecular genetics from the university of Cambridge and a Diploma (MSc) in biochemistry from Freie Universität Berlin, Germany. He serves on the advisory boards of Polpharma Biologics' novel antibodies spin-off JJP biologics and of Nodal Therapeutics.